A blockbuster cancer drug? TYK’s claims go under the microscope 头对头试验胜过“肺癌药王”？同源康医药临床结果引争议
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme 同源康医药公布重大利好消息后的第一个交易日，也是该股被纳入港股通名单生效的第一天。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.